Alzheimer’s disease(AD)has become an important public health issue worldwide.p-Coumaric acid(CA)and lactoferrin(Lf)possessed antioxidant,anti-inflammatory,and anti-AD activities.Herein,we hypothesized that a combinat...Alzheimer’s disease(AD)has become an important public health issue worldwide.p-Coumaric acid(CA)and lactoferrin(Lf)possessed antioxidant,anti-inflammatory,and anti-AD activities.Herein,we hypothesized that a combination treatment of CA and Lf would synergistically improve AD symptoms and studied its mechanisms.Twelve-week-old amyloid precursor protein(APP)/presenilin 1(PS1)mice were treated with CA,Lf,or both CA and Lf for 8 weeks.Results showed that individual and combined treatments could ameliorate cognitive deficits to varying degrees,with stronger effects for combined intervention than for CA or Lf alone.Specifically,combined treatment was most effective in improving nesting ability and reducing amyloidββ_(1-42)(Aβ_(1-42))deposition in mice.Moreover,combined treatment was more effective in suppressing APP,β-site APP cleavage enzyme 1,and inflammation;it inhibited the CCAAT-enhancer-binding protein(C/EBPβ)/asparagine endopeptidase(AEP)signaling pathway in the hippocampus and colon and upregulated the expression of tight junction protein zonula occludens-1 in the colon;it also decreased the Firmicutes/Bacteroidetes ratio at the phylum level and increased the relative abundance of Prevotellaceae,Lachnospira,and Eubacterium at the genus level.Overall,the combination of CA and Lf may ameliorate cognitive deficits in APP/PS1 mice by improving inflammation and inhibiting the C/EBPβ/AEP signaling pathway via modulating gut microbiome.展开更多
Parkinson’s disease is a neurodegenerative disease characterized by motor and gastrointestinal dysfunction.Gastrointestinal dysfunction can precede the onset of motor symptoms by several years.Gut microbiota dysbiosi...Parkinson’s disease is a neurodegenerative disease characterized by motor and gastrointestinal dysfunction.Gastrointestinal dysfunction can precede the onset of motor symptoms by several years.Gut microbiota dysbiosis is involved in the pathogenesis of Parkinson’s disease,whether it plays a causal role in motor dysfunction,and the mechanism underlying this potential effect,remain unknown.CCAAT/enhancer binding proteinβ/asparagine endopeptidase(C/EBPβ/AEP)signaling,activated by bacterial endotoxin,can promoteα-synuclein transcription,thereby contributing to Parkinson’s disease pathology.In this study,we aimed to investigate the role of the gut microbiota in C/EBPβ/AEP signaling,α-synuclein-related pathology,and motor symptoms using a rotenone-induced mouse model of Parkinson’s disease combined with antibiotic-induced microbiome depletion and fecal microbiota transplantation.We found that rotenone administration resulted in gut microbiota dysbiosis and perturbation of the intestinal barrier,as well as activation of the C/EBP/AEP pathway,α-synuclein aggregation,and tyrosine hydroxylase-positive neuron loss in the substantia nigra in mice with motor deficits.However,treatment with rotenone did not have any of these adverse effects in mice whose gut microbiota was depleted by pretreatment with antibiotics.Importantly,we found that transplanting gut microbiota derived from mice treated with rotenone induced motor deficits,intestinal inflammation,and endotoxemia.Transplantation of fecal microbiota from healthy control mice alleviated rotenone-induced motor deficits,intestinal inflammation,endotoxemia,and intestinal barrier impairment.These results highlight the vital role that gut microbiota dysbiosis plays in inducing motor deficits,C/EBPβ/AEP signaling activation,andα-synuclein-related pathology in a rotenone-induced mouse model of Parkinson’s disease.Additionally,our findings suggest that supplementing with healthy microbiota may be a safe and effective treatment that could help ameliorate the progression of motor deficits in patients with Parkinson’s disease.展开更多
基金funded by the National Natural Science Foundation of China(82103818)the Suzhou Applied Basic Research(Medical and Health)Science and Technology Innovation Project(SYW2024179)+1 种基金Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-communicable Diseases,Soochow University(KJS2437)the Priority Academic Program Development of Jiangsu Higher Education Institutions(PAPD).
文摘Alzheimer’s disease(AD)has become an important public health issue worldwide.p-Coumaric acid(CA)and lactoferrin(Lf)possessed antioxidant,anti-inflammatory,and anti-AD activities.Herein,we hypothesized that a combination treatment of CA and Lf would synergistically improve AD symptoms and studied its mechanisms.Twelve-week-old amyloid precursor protein(APP)/presenilin 1(PS1)mice were treated with CA,Lf,or both CA and Lf for 8 weeks.Results showed that individual and combined treatments could ameliorate cognitive deficits to varying degrees,with stronger effects for combined intervention than for CA or Lf alone.Specifically,combined treatment was most effective in improving nesting ability and reducing amyloidββ_(1-42)(Aβ_(1-42))deposition in mice.Moreover,combined treatment was more effective in suppressing APP,β-site APP cleavage enzyme 1,and inflammation;it inhibited the CCAAT-enhancer-binding protein(C/EBPβ)/asparagine endopeptidase(AEP)signaling pathway in the hippocampus and colon and upregulated the expression of tight junction protein zonula occludens-1 in the colon;it also decreased the Firmicutes/Bacteroidetes ratio at the phylum level and increased the relative abundance of Prevotellaceae,Lachnospira,and Eubacterium at the genus level.Overall,the combination of CA and Lf may ameliorate cognitive deficits in APP/PS1 mice by improving inflammation and inhibiting the C/EBPβ/AEP signaling pathway via modulating gut microbiome.
基金supported by Jiangsu Provincial Medical Key Discipline,No.ZDXK202217(to CFL)Jiangsu Planned Projects for Postdoctoral Research Funds,No.1601056C(to SL).
文摘Parkinson’s disease is a neurodegenerative disease characterized by motor and gastrointestinal dysfunction.Gastrointestinal dysfunction can precede the onset of motor symptoms by several years.Gut microbiota dysbiosis is involved in the pathogenesis of Parkinson’s disease,whether it plays a causal role in motor dysfunction,and the mechanism underlying this potential effect,remain unknown.CCAAT/enhancer binding proteinβ/asparagine endopeptidase(C/EBPβ/AEP)signaling,activated by bacterial endotoxin,can promoteα-synuclein transcription,thereby contributing to Parkinson’s disease pathology.In this study,we aimed to investigate the role of the gut microbiota in C/EBPβ/AEP signaling,α-synuclein-related pathology,and motor symptoms using a rotenone-induced mouse model of Parkinson’s disease combined with antibiotic-induced microbiome depletion and fecal microbiota transplantation.We found that rotenone administration resulted in gut microbiota dysbiosis and perturbation of the intestinal barrier,as well as activation of the C/EBP/AEP pathway,α-synuclein aggregation,and tyrosine hydroxylase-positive neuron loss in the substantia nigra in mice with motor deficits.However,treatment with rotenone did not have any of these adverse effects in mice whose gut microbiota was depleted by pretreatment with antibiotics.Importantly,we found that transplanting gut microbiota derived from mice treated with rotenone induced motor deficits,intestinal inflammation,and endotoxemia.Transplantation of fecal microbiota from healthy control mice alleviated rotenone-induced motor deficits,intestinal inflammation,endotoxemia,and intestinal barrier impairment.These results highlight the vital role that gut microbiota dysbiosis plays in inducing motor deficits,C/EBPβ/AEP signaling activation,andα-synuclein-related pathology in a rotenone-induced mouse model of Parkinson’s disease.Additionally,our findings suggest that supplementing with healthy microbiota may be a safe and effective treatment that could help ameliorate the progression of motor deficits in patients with Parkinson’s disease.
